Aquestive Therapeutics (AQST) EBT (2017 - 2026)

Aquestive Therapeutics' EBT history runs 10 years deep, the most recent figure standing at -$8.1 million for Q1 2026.

• On a quarterly basis, EBT rose 64.86% year-over-year to -$8.1 million in Q1 2026; TTM through Mar 2026 was -$68.9 million, a 27.02% decrease from a year earlier, with the FY2025 full-year figure at -$83.8 million, down 89.77% from the prior year.
• EBT advanced to -$8.1 million in Q1 2026 per AQST's latest filing, from -$31.9 million in the prior quarter.
• Across five years, EBT topped out at $8.1 million in Q1 2023 and bottomed at -$31.9 million in Q4 2025.
• The 5-year median for EBT is -$12.5 million (2022), against an average of -$11.6 million.
• Across the five-year window, EBT jumped 161.03% in 2023 and sank 429.15% in 2024, its largest moves.
• Year by year, EBT stood at -$12.4 million in 2022, then surged by 35.15% to -$8.0 million in 2023, then plunged by 113.1% to -$17.1 million in 2024, then slumped by 86.65% to -$31.9 million in 2025, then surged by 74.71% to -$8.1 million in 2026.
• Per Business Quant, the three latest AQST EBT figures stand at -$8.1 million (Q1 2026), -$31.9 million (Q4 2025), and -$15.4 million (Q3 2025).